Sustained rheumatoid arthritis remission is uncommon in clinical practice

Overview of attention for article published in Arthritis Research & Therapy, January 2012

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#2 of 3,056)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 650 news stories from 117 outlets.

The New England Journal of Medicine today published detailed results from Eli Lilly and Company's (NYSE: LLY) phase 2a study of…

Peresolimab met the primary efficacy endpoint in patients with refractory rheumatoid arthritis (RA) Study evaluated a novel…

Peresolimab met the primary efficacy endpoint in patients with refractory rheumatoid arthritis (RA) Study evaluated a novel…

Peresolimab met the primary efficacy endpoint in patients with refractory rheumatoid arthritis (RA) Study evaluated a novel…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 646 additional news stories.